Hucold-LM Syrup is a combination pharmaceutical formulation containing Levocetirizine 2.5 mg and Montelukast 4 mg per dose, designed for the management of allergic conditions and respiratory disorders. Levocetirizine, a third-generation non-sedating antihistamine, selectively antagonizes peripheral H1 receptors, effectively reducing symptoms such as rhinorrhea, sneezing, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, inhibits cysteinyl leukotriene D4 at the CysLT1 receptor, thereby preventing bronchoconstriction, inflammation, and edema in the airways. The synergistic action of these agents makes Hucold-LM Syrup suitable for treating pediatric patients with allergic rhinitis, asthma, and other hypersensitivity reactions where both histamine and leukotriene pathways contribute to symptomatology. The syrup formulation facilitates ease of administration and dose adjustment in children. Hucold-LM Syrup should be used under medical supervision, with caution in patients with hepatic or renal impairment. Common adverse effects may include headache, somnolence, gastrointestinal disturbances, and rarely neuropsychiatric symptoms. It is contraindicated in patients with known hypersensitivity to either component. Regular monitoring and adherence to prescribed dosage ensure optimal therapeutic outcomes and safety.